Clinical Trials
79
Trial Phases
4 Phases
Drug Approvals
4
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (37 trials with phase data)• Click on a phase to view related trials
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 47
- Registration Number
- NCT07053345
- Locations
- 🇰🇷
Cha Ilsan Medical Center, Goyang Si Gyeonggi Do, Korea, Republic of
🇰🇷Wonkwang University Hospital, Iksan, Korea, Republic of
🇰🇷Kyung Hee University Medical Center, Seoul, Korea, Republic of
A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants
- Conditions
- Chronic Graft vs Host Disease
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 15
- Registration Number
- NCT04852692
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Korea, Republic of
🇰🇷Soonchunhyang University Bucheon Hospital, Bucheon-Si, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
A Study of the Newly Formulated Tylenol Tablet (Acetaminophen) to the Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 30
- Registration Number
- NCT04230252
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Korea, Republic of
A Study of Newly Formulated Tylenol Tablet (Acetaminophen) and Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 30
- Registration Number
- NCT04214691
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Korea, Republic of
Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 685
- Registration Number
- NCT03942120
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Korea, Republic of
🇰🇷Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Inje University Haeundae Paik Hospital, Busan, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 16
- Next